PCT -  World Patents in Skin Care Actives Published in 2007

Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

PCT - World Patents in Skin Care Actives Published in 2007


TOPICAL PHARMACEUTICAL FORMULATIONS

(WO2007148116) 27.12.2007 A61K 9/20 ASTON UNIVERSITY
A granular pharmaceutical formulation for topical administration to an animal, comprising: (a) a pharmaceutically acceptable carrier; (b) a therapeutically effective amount of a therapeutic agent; (c) a hydrophilic nonionic surfactant; and optionally: (d) a carbomer; and/or (e) a penetration enhancer selected from essential oils, terpenes and terpenoids; said formulation being solid at ambient temperature and having a softening point of not higher than 35C.
--------------------------------------------------------------------------------

USE CATHELICIDIN ANTIMICROBIAL PROTEIN (HCAP18 ) AS ANTICANCER AGENT

(WO2007148078) 27.12.2007 A61K 38/17 LIPOPEPTIDE AB
The present invention provides the use of a polypeptide comprising an amino acid sequence according to SEQ ID NO: 1 (corresponding to the N-terminal 25 amino acid fragment of the human antimicrobial protein, LL-37) or a biologically active fragment, variant, fusion or derivative thereof, in the preparation of a medicament for the treatment of cancer. In particular, the inventions provides the use such polypeptides, or a fragment, variant, fusion or derivative thereof, to inhibit the proliferation and/or metastasis of cancer cells, such as breast cancer cells. The invention further comprises methods for the treatment of cancer in a patient.
--------------------------------------------------------------------------------

PEPTIDE FRAGMENTS FOR INDUCING SYNTHESIS OF EXTRACELLULAR MATRIX PROTEINS

(WO2007146269) 21.12.2007 C07K 14/78 HELIX BIOMEDIX INC.
[0049] Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.
--------------------------------------------------------------------------------

INFUSED SPONGE DELIVERY SYSTEM

(WO2007146103) 21.12.2007 A61K 9/70 SPONGEABLES, LLC
A method for delivering active ingredients to a wet substrate from a flexible, three- dimensional, water-absorbent substrate material comprised of a web of substantially water-insoluble fibers into which is infused a solid anhydrous composition having a melting point of from about 45C to about 55C said anhydrous composition comprising (i) at least one surfactant selected from the group consisting of cationic quaternary surfactants, anionic surfactants or nonionic surfactants or one multi-lamellar liquid crystal emulsifier system, (ii) at least one fatty alcohol, (iii) at least one emollient selected from the group consisting of cosmetically-acceptable oils, esters and liquid triglycerides, (iv) at least one active ingredient and (v) opt...
--------------------------------------------------------------------------------

COSMETIC USE OF ACTIVE INGREDIENTS INCREASING THE PRODUCTION OF GROWTH FACTORS

(WO2007144325) 21.12.2007 A61Q 19/08 CHANEL PARFUMS BEAUTE
The invention relates to a cosmetic skin care method, intended to prevent and/or treat at least one cutaneous sign of ageing, including topical application to the skin of a composition containing at least one botanical active ingredient which increases the production by keratinocytes of at least one growth factor chosen from bFGF and PDGF.
--------------------------------------------------------------------------------

COSMETIC USE OF A CASSUMUNARIN, AN ARYLBUTENOID, AND/OR A BOTANICAL EXTRACT CONTAINING THEM

(WO2007144270) 21.12.2007 A61K 8/35 CHANEL PARFUMS BEAUTE
The present invention relates to a cosmetic skin care method to prevent and/or treat at least one sign of skin ageing, comprising the topical application to the skin of a composition comprising at least one active ingredient selected from cassumunarin and/or an arylbutenoid and/or a botanical extract containing them, such as an extract from Zingiber cassumunar Roxb. It also pertains to an extract from Zingiber cassumunar Roxb, which is obtainable by extracting rhizomes thereof with at least one apolar solvent having a polarity index of less than 1, optionally mixed with at least one polar solvent having a polarity index of more than 3.5.
--------------------------------------------------------------------------------

NOVEL SILICONE FILM FORMER FOR DELIVERY OF ACTIVES

(WO2007139812) 06.12.2007 H01L 51/00 DOW CORNING CORPORATION
The invention provides: a film-forming composition comprising a) a saccharide- siloxane copolymer; b) a crossl inking agent; c) one or more active/inactive ingredients; and d) optionally, a solvent, or solvent mixture, wherein the the saccharide-siloxane copolymer has the following formula: R2aR1(3-a)SiO-[( SiR2R1O)m-( SiR12O)n ]y- SiR1(3-a) R2a that is further formulaically defined and wherein the saccharide-siloxane copolymer is a reaction product of a functionalized organosiloxane polymer and at least one hydroxy-functional saccharide such that the organosiloxane component is covalently linked via a linking group to the saccharide component; films; and methods related thereto. The invention also provides articles of manufacture including...
--------------------------------------------------------------------------------

FORMULATION CONTAINING NECK DOMAINS AND/OR CARBOHYDRATE RECOGNITION DOMAINS FOR COSMETIC APLICATIONS, NAMELY FOR THE TREATMENT OF KERATIN FIBRES LIKE HAIR

(WO2007136286) 29.11.2007 A61K 8/64 UNIVERSIDADE DO MINHO
The present invention describes an innovative formulation for cosmetic applications, namely hair treatment, in which neck and/or carbohydrate recognition domains are incorporated in order to increase hair properties while reducing and repairing eventual damages on hair. As recognition domains a protein hydrolyzate from a milk protein, some human surfactant proteins and some synthetic biologically active peptides were used.
--------------------------------------------------------------------------------

TREATMENT OF A WOUND WITH A VASODILATOR

(WO2007134123) 22.11.2007 A61K 38/00 BANNER HEALTH
A wound treatment administers a vasodilator by: (a) active transdermal treatment such as: by direct perfusion of the wound with the vasodilator, by an intradermal injection of the vasodilator about the wound and its surrounding skin area, by iontophoresis about the wound and its surrounding skin area with the vasodilator, by microdialysis of the wound with the vasodilator using one or more probe situated about the wound and its surrounding skin area; and/or by (b) passive transdermal treatment such as: by transcutaneous electrical stimulation (TENS) about the wound and its surrounding skin area while administering the vasodilator, or by a combination of the foregoing. The vasodilator can be calcitonin gene-related peptide (CGRP) with or wit...
--------------------------------------------------------------------------------

WATER IN OIL EMULSION COMPOSITIONS CONTAINING SUNSCREEN ACTIVES AND SILOXANE ELASTOMERS

(WO2007133769) 22.11.2007 A61Q 19/00 THE PROCTER &GAMBLE COMPANY
The present invention relates to water in oil emulsion compositions suitable for use as sunscreen comprising: from about 0.1% to about 15% of an emulsifying crosslinked siloxane elastomer; from about 1% to about 40% of a solvent for the emulsifying crosslinked siloxane elastomer; from about 0.01% to about 5% of an additional emulsifier; from about 50% to about 99% of aqueous phase; and from about 0.01% to about 30% of a sunscreen active; wherein when shear stress is applied to the composition during spreading on skin, aqueous phase is released from the emulsion.
--------------------------------------------------------------------------------

METHOD OF ENHANCING PENETRATION OF WATER-SOLUBLE ACTIVES

(WO2007133768) 22.11.2007 A61K 8/894 THE PROCTER &GAMBLE COMPANY
A method of enhancing the delivery of water-soluble skin care actives into keratinous tissue, comprising the step of applying to the keratinous tissue a water-in-oil emulsion comprising an aqueous phase and a non-aqueous phase, wherein the aqueous phase comprises a water-soluble skin care active, and whereupon application of shear stress to the composition, the aqueous phase is visibly separated from the non-aqueous phase.
--------------------------------------------------------------------------------

WATER-DISPERSIBLE PATCH CONTAINING AN ACTIVE AGENT FOR DERMAL DELIVERY

(WO2007133509) 22.11.2007 A61K 8/02 EASTMAN CHEMICAL COMPANY
A dermal patch having comprising at least two layers wherein at least one layer is a polymer matrix system having an active agent admixed therein. At least one of the layers includes a water-dispersible or water-dissipatable polymer. The dermal patch has an elongation factor of at least 50 %.
--------------------------------------------------------------------------------

WATER DISPERSIBLE FILMS FOR DELIVERY OF ACTIVE AGENTS TO THE EPIDERMIS

(WO2007133508) 22.11.2007 C08G 63/00 EASTMAN CHEMICAL COMPANY
A water-dissipatable film fopning formulation includes a polymer having at least one water solubilizing or dissipating moiety; an active ingredient or agent; and at least one of a plasticizer or a humectant. The present invention also includes a method for delivering an active agent to the epidermis of a subject. The method includes applying the film forming formulation to a predetermined area of skin.
--------------------------------------------------------------------------------

RINSE-OFF THERAPEUTIC AGENTS FOR TREATING SKIN

(WO2007132273) 22.11.2007 A61K 8/31 RECKITT &COLMAN (OVERSEAS) LIMITED
A rinse-off composition suitable for topical application comprising a skincare active ingredient capable of regulating the barrier properties of the skin and a carrier therefor, said carrier comprising a) a physiologically acceptable oil present in an amount of at least 25% by weight of the composition; b) a surfactant selected from an anionic surfactant, a non-ionic surfactant or a mixture thereof; and c) a miscible non-aqueous film former. The invention particularly relates to skincare active ingredients which are substantially insoluble in water. The composition is especially useful in the treatment of eczema, psoriasis, rosacea-prone skin, inflamed skin and acne. On applying the composition to the skin and rinsing off, an emulsion is fo...
--------------------------------------------------------------------------------

COMPOSITION FOR TRANSDERMAL ABSORPTION AND FORMULATION COMPRISING A POLYMERIC MATRIX FORMED THEREFROM

(WO2007129837) 15.11.2007 A61K 9/70 AMOREPACIFIC CORPORATION
The inventive composition for transdermal absorption characterized by comprising a nonsteroidal anti-inflammatory drug as an active ingredient together with an alkali metal-containing alcohol derivative as a solubilizing agent for the active ingredient comprises a high concentration of the active ingredient while using only a small amount of the solvent, and a transdermal absorption formulation comprising a polymeric matrix formed from the composition is capable of maximizing the skin absorption of the active ingredient with minimal skin irritation.
--------------------------------------------------------------------------------

NEW COSMETIC COMPOSITIONS COMPRISING AT LEAST ONE PEPTIDE WITH AT LEAST ONE IMMOBILIZED AROMATIC CYCLE

(WO2007129270) 15.11.2007 A61K 8/00 SEDERMA
Topical cosmetic use as a whitening active ingredient of at least one peptide, comprising at least one immobilized aromatic cycle and having the general formula (I): A-(Xa)m-Xc-(Xb)n-B. The invention also discloses a cosmetic composition comprising at least said peptide and a method of decreasing skin pigmentation, whitening or lightening human skin, comprising a topical application of said composition.
--------------------------------------------------------------------------------

PERSONAL CARE ARTICLE

(WO2007128983) 15.11.2007 A61Q 7/02 RECKITT BENCKISER (UK) LIMITED
A personal care article including a substrate having impregnated therein, applied thereon or arranged to substantially encase, a cosmetic composition which includes a hair modification active, wherein the pH of the composition is substantially less than 9.0, and at least a portion of the article has exfoliating properties.
--------------------------------------------------------------------------------

DRUG RELEASE FROM NANOPARTICLE-COATED CAPSULES

(WO2007128066) 15.11.2007 A61K 9/107 UNIVERSITY OF SOUTH AUSTRALIA
Methods of producing a controlled release formulation for an active substance are disclosed, wherein the methods involve dispersing a discontinuous phase comprising an active substance into a continuous phase so as to form a two-phase liquid system comprising droplets of said discontinuous phase, and allowing nanoparticles provided to the two-phase liquid system to congregate at the phase interface to thereby coat the surface of the droplets in at least one layer of said nanoparticles. The methods utilise a concentration of a suitable electrolyte which enhances the nanoparticle congregation such that the coating of nanoparticles on the surface of the droplets presents a semi- permeable barrier to the active substance, or otherwise utilise a...
--------------------------------------------------------------------------------

NEW APPROACH TO THE TREATMENT OF COMPARTMENT SYNDROME

(WO2007126363) 08.11.2007 A61K 38/17 LANTMNNEN AS-FAKTOR
The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may be caused by or a cause of a variety of other conditions which are also encompassed by the present invention, such as viral and bacterial infections. Furthermore, the invention relates to a method for the treatment and/or prevention of compartment syndrome in a mammal in need thereof.
--------------------------------------------------------------------------------

ANTAGONIST ANTI-CD40 ANTIBODY PHARMACEUTICAL COMPOSITIONS

(WO2007124299) 01.11.2007 A61K 39/00 NOVARTIS AG
Stable liquid pharmaceutical compositions comprising an antagonist anti- CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody -containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.
--------------------------------------------------------------------------------

STABLE SOLUTIONS OF PROSTAGLANDIN AND USES OF SAME

(WO2007123867) 01.11.2007 A61K 31/557 KEPKA, Stanley
Novel compositions that include therapeutic amounts of prostaglandin, such as compounds of the PG-E type in anhydrous, water-miscible pharmacologically acceptable solvent systems are introduced, as well as methods and apparatus for dispensing such compounds. The methods and apparatus involve dissolving an active ingredient in an anhydrous, water-miscible pharmacologically acceptable solvent system, packaging the resultant solution in unit dose containers, diluting the contents of the container into a liquid or solid vehicle, and administering a therapeutic dose. The invention provides room-temperature stable non-aqueous Alprostadil (prostaglandin-E) in dosage forms suitable for the treatment of sexual dysfunction. The stable solution is att...
--------------------------------------------------------------------------------

BIOAVAILABILITY ENHANCEMENT OF LIPOPHILIC DRUG BY USE SOLVENT SYSTEM

(WO2007120868) 25.10.2007 A61K 6/00 KEPKA, Stanley
Compositions and methods for improving the efficacy and/or transdermal transport of topically administered pharmacologically active compounds are disclosed. Preferably, the pharmacologically active compound is incorporated in a carrier comprising an effective amount of a lipophilic pharmaceutically acceptable compound selected from the group consisting of alcohol, glycols, ethers and mixtures thereof, most preferably benzyl alcohol. In certain embodiments, compositions and methods of treatment for anti-fungal compositions are disclosed that exhibit enhanced permeation. In another embodiment and improved, stable topical composition of prostaglandin is disclosed.
--------------------------------------------------------------------------------

TOPICAL THERAPEUTIC DELIVERY SYSTEM

(WO2007117352) 18.10.2007 A61K 8/36 MURAD, Howard
An oil-in-water emulsion topical delivery system comprising (i) an oil phase; (ii) an aqueous phase; (iii) phenoxyethanol at a concentration of from about 2.0% to about 2.7% based on the total weight of the composition; (iv) an effective exfoliating amount of a hydrophobic hydroxycarboxylic acid selected from the group consisting of orthohydroxybenzoic acid, hydroxycarboxylic acids containing a C12 -C24 fatty acid esterified to the alpha carbon hydroxyl group, and hydroxycarboxylic acids containing a C12 -C24 fatty alcohol esterified to a carboxyl group; (v) a non-ionic emulsifier having an HLB of from about 7 to about 10; and (vi) at least one skin-supporting or dermatopharmaceutically active agent.
--------------------------------------------------------------------------------

DOSE PACKAGING SYSTEM FOR LOAD-DOSE TITRATION ADMINISTRATION OF A LIQUID FORMULATION

(WO2007109684) 27.09.2007 H01M 8/16 PRE HOLDING, INC.
The invention generally relates to a dose packaging system for the administration of a liquid formulation to a patient requiring load-dose titration therapy of a pharmaceutically active drug, such as steroid therapy. More particularly, the invention relates to a dose packaging system for administering titration therapy of liquid formulations to a patient which eliminates the disadvantages that are associated with cups, dosing spoons, calibrated oral syringes and bottles.
--------------------------------------------------------------------------------

FIBRIN MICROTHREADS

(WO2007109137) 27.09.2007 A61L 27/56 WORCESTER POLYTECHNIC INSTITUTE
Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., RGD-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells. Also provided are methods of making compositions that include fibrin microthreads. Also provided are methods for using the compositions to repair or ameliorate damaged or defective organs or tissues.
--------------------------------------------------------------------------------

REMOVAL OF SKIN CHANGES

(WO2007107809) 27.09.2007 A61Q 19/00 GALIC, Borivoj
The present invention relates to the field of skin disorders, particularly to the prevention and/or treatment of benignant or malignant changes of the epidermis visible in form of e.g. nevus. A pharmaceutical, dermatological and/or cosmetic composition is disclosed comprising as active constituent the boroxine compound. The present invention further provides the respective uses of the boroxine compound in medicine, particularly in the field of skin disorders, and in dermatological and/or cosmetic applications.
--------------------------------------------------------------------------------

COSMETIC COMPOSITION COMPRISING A COMBINATION OF A SUGAR FATTY ACID ESTER WITH A PLANT EXTRACT OF WALTHERIA INDICA OR PISUM SATIVUM FOR SKIN WHITENING

(WO2007107268) 27.09.2007 A61K 8/60 COGNIS IP MANAGEMENT GMBH
The invention is directed to a skin-whitening active comprising at least one sugar fatty acid ester and at least one plant extract selected from the group consisting of extracts of Waltheria indica, extracts of Pisum sativum and mixtures thereof. The invention is further directed to cosmetic compositions comprising such a skin- whitening active.
--------------------------------------------------------------------------------

COMBINED ENERGY AND TOPICAL COMPOSITION APPLICATION FOR REGULATING THE CONDITION OF MAMMALIAN SKIN

(WO2007106501) 20.09.2007 A61K 8/34 THE PROCTER &GAMBLE COMPANY
Method for regulating the condition of mammalian skin comprising the steps of applying a first personal care composition to an area of skin where regulation is desired, wherein the first personal care composition comprises at least one skin care active selected from the group consisting of niacinamide, salicylic acid, peptides, N-acetyl glucosamine, panthenol, butylated hydroxytoluene, N-acyl amino acid compounds, hexamidine, green tea, ascorbyl glucoside, hexanediol, pentanediol, a skin lightening agent, a heat shock protein potentiator, and mixtures thereof; and delivering energy to the area of skin by contacting the skin with an energy delivery device for a treatment period of at least 2 minutes, wherein the energy delivery device ...
--------------------------------------------------------------------------------

SILICONE BASED EMULSIONS FOR TOPICAL DRUG DELIVERY

(WO2007106284) 20.09.2007 A61K 8/89 DOW PHARMACEUTICAL SCIENCES, INC.
A water-in-oil emulsion is provided in which the lipophilic phase of the emulsion contains a silicone fluid and an emulsifier, a hydrophilic phase, and a pharmaceutically active compound. The active pharmaceutical ingredient is dissolved or dispersed in the emulsion and is partitioned in the emulsion so that all or a portion of the amount of the chemical compound dissolved or dispersed in the emulsion is dissolved or dispersed in the aqueous phase of the emulsion. The emulsion of the invention provides increased penetration into skin of the chemical compound dissolved or dispersed in the aqueous phase.
--------------------------------------------------------------------------------

METHODS FOR REGULATING INFLAMMATORY MEDIATORS AND PEPTIDES USEFUL THEREIN

(WO2007103368) 13.09.2007 A61K 38/16 BIOMARCK PHARMACEUTICALS, LTD.
The present invention includes methods of modulating cellular secretory processes. More specifically the present invention relates to modulating or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from the vesicles or granules in the inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. MANS peptide and active fragments thereof are useful in such methods.
--------------------------------------------------------------------------------

FOAM CONTAINING UNIQUE OIL GLOBULES

(WO2007102052) 13.09.2007 None FOAMIX LTD.
The present invention provides a foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable oil in water emulsion composition includes: an oil globule system, selected from the group consisting of oil bodies; and sub-micron oil globules, about 0.1 % to about 5% by weight of an agent, selected from the group consisting of a surface-active agent, having an HLB value between 9 and 16; and a polymeric agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, water and optional ingredients are added to complete the total mass to 100%. Up...
--------------------------------------------------------------------------------

TRANSDERMAL PATCHES CONTAINING A NITRIC OXIDE-DONOR AND A SECOND ACTIVE AGENT AND ASSOCIATED METHODS

(WO2007100910) 07.09.2007 A61K 9/70 CURE THERAPEUTICS, INC.
The present invention is drawn to a transdermal patch for the delivery of a nitric oxide-donor and a second active agent. The patch can comprise a backing layer and an active agent-containing composition which is supported at least in part by the backing layer. The active agent-containing composition can include an amount of a nitric oxide-donor and an amount of a second active agent. The transdermal patch can have a drug delivery zone defined by the area where the composition contacts an intact human skin site, and the transdermal patch can be formulated to deliver a nitric oxide donor, such as nitroglycerin, at from about 5 g/hour to about 85 g/hour. The second active agent can be selected from a number of agents including NSAID...
--------------------------------------------------------------------------------

SILICONE VESICLES CONTAINING ACTIVES

(WO2007100416) 07.09.2007 A61K 8/14 DOW CORNING CORPORATION
A process is disclosed for preparing a hydrophobic active loaded vesicle composition by admixing a hydrophobic active to a pre-formed silicone vesicle dispersion. The silicone vesicle compositions are useful in a variety of personal and healthcare compositions.
--------------------------------------------------------------------------------

METHODS AND COMPOSITIONS FOR TREATMENT OF SKIN

(WO2007099398) 07.09.2007 A61K 45/00 NATURALITE BENELUX B.V.
The present invention relates to compositions and their use for the treatment of human skin, particularly facial skin, to alleviate the symptoms of cosmetic or determatologic skin conditions. The invention relates to compositions for treating and ameliorating skin conditions including acne, rosacea and wrinkling caused by photodamage or conditions related to aging, hormonal imbalances, hyper-pigmentation, melasma, keratosis or the like. The invention can also be used to treat conditions of the scalp such as dandruff. The present invention also relates to compositions that can be used to remove biofllms from contact lenses. More particularly, this invention relates to a composition comprising (a) one or more metasilicate; (b) one or more car...
--------------------------------------------------------------------------------

ANTIBIOTIC KIT AND COMPOSITION AND USES THEREOF

(WO2007099396) 07.09.2007 None FOAMIX LTD.
The present invention relates to a therapeutic kit to provide a safe and effective dosage of an antibiotic agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition including: an antibiotic agent; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2 % to about 50 % by weight, a surface- active agent, about 0.01 % to about 5 % by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent...
--------------------------------------------------------------------------------

MELATONIN AND IMMUNOSTIMULATING SUBSTANCE-BASED COMPOSITIONS

(WO2007099172) 07.09.2007 A61K 31/07 MAVI SUD S.R.L.
The present invention relates to synergistic associations of melatonin and other active substances and cosmetic compositions suitable for treating all those manifestations causing or accompanying the aging of skin, hair and other tissues. In particular, the invention is based on the use of melatonin associated with immunoactive and antioxidant substances significantly potentiating its antiaging activity, remarkably reducing free radical formation and thereby improving the aspect of both skin and hair.
--------------------------------------------------------------------------------

WOUND CARE ARTICLES, DRUG DELIVERY SYSTEMS AND METHODS OF USING THE SAME

(WO2007092350) 16.08.2007 A61F 13/00 H.B. FULLER LICENSING & FINANCING, INC.
A wound care article that includes a hot melt superabsorbent polymer composition that includes a thermoplastic polymer, superabsorbent polymer particles and optionally at least one physiologically active agent, a prodrug or a combination thereof, a liquid permeable layer, a first liquid permeable, superabsorbent particle impermeable barrier, a second liquid permeable superabsorbent particle impermeable barrier, and a liquid impermeable layer. A drug delivery system that includes a first hot melt superabsorbent polymer composition that includes thermoplastic polymer and superabsorbent polymer particles, and at least one physiologically active agent, prodrug or combination thereof.
--------------------------------------------------------------------------------

FRAGRANCED THERAPEUTIC DELIVERY SYSTEM

(WO2007092085) 16.08.2007 A61K 8/36 MURAD, Howard
The present invention relates to multi-functional topical delivery systems for providing long-lasting delivery of fragrance as. well as skin-supporting and/or pharmaceutically active ingredients comprising (i) an oil phase; (ii) an aqueous phase; (iii) phenoxyethanol at a concentration of from about 2.0% to about 2.7% based on the total weight of the composition; (iv) an effective exfoliating amount of a hydrophobic hydroxycarboxylic acid selected from the group consisting of orthohydroxybenzoic acid, hydroxycarboxylic acids containing a C12 - C24 fatty acid esterified to the alpha carbon hydroxyl group, hydroxycarboxylic acids containing a C12 - C24 fatty alcohol esterified to a carboxyl group; (v) a non-ionic emulsifier having an HLB of f...
--------------------------------------------------------------------------------

ANTI-AGING TREATMENT USING COPPER AND ZINC COMPOSITIONS

(WO2007089267) 09.08.2007 A61K 33/34 JR CHEM, LLC
Composition and methods for alleviating or eliminating age related skin conditions by providing an effective amount of one or more copper, zinc and copper- zinc compositions are disclosed. Treatment is accomplished through the use of topical compositions containing one or more copper or zinc salts and/or copper-zinc compounds or complexes, particularly copper-zinc malonate active ingredient.
--------------------------------------------------------------------------------

COMPOSITION FOR PROMOTING VASCULAR SMOOTH MUSCLE RELAXATION

(WO2007088327) 09.08.2007 A61K 9/06 FUTURA MEDICAL DEVELOPMENTS LIMITED
A composition for topical application to a part of the body comprises a local anaesthetic and optionally a vasodilator as active ingredient dissolved in a blend of volatile and non-volatile solvents of different solvating capacities for the active ingredient. The vasodilator may comprise glyceryl trinitrate and the local anaesthetic may comprises an anaesthetic of the aminoamide or aminoester type. The volatile solvent may comprise a mixture of water with a C1-C5 alcohol and the non-volatile solvent may comprise a polyhydric alcohol and optionally a glycol. A low-concentration vasodilator-containing composition is also described. The compositions allow a virtual injection of the active ingredient to be delivered transdermally ...
--------------------------------------------------------------------------------

FOAMABLE COMPOSITION COMBINING A POLAR SOLVENT AND A HYDROPHOBIC CARRIER

(WO2007085902) 02.08.2007 None FOAMIX LTD.
The present invention relates to a foamable vehicle or cosmetic or pharmaceutical composition, comprising: (1) an organic carrier, at a concentration of 10% to 70% by weight, wherein said organic carrier concurrently comprises: (i) at least one hydrophobic organic carrier, and (ii) at least one polar solvent; (2) at least one surface-active agent; (3) water; and (4) at least one liquefied or compressed gas propellant at a concentration of 3% to 25% by weight of the total composition. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering the above-mentioned compositions to an afflicted target site.
--------------------------------------------------------------------------------

NON-FLAMMABLE INSECTICIDE COMPOSITION AND USES THEREOF

(WO2007085899) 02.08.2007 None FOAMIX LTD.
The present invention provides a safe and effective insecticide composition suitable for treating a subject infested with a parasitic anthropode or to prevent infestation by an arthropod. The insecticide composition is a foamable composition, including a first insecticide; at least one organic carrier selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 5%, or about 5% to about 10%;or about 10% to about 20%; or about 20% to about 50% by weight; about 0.1 % to about 5% by weight of a surface-active agent; about 0.01 % to about 5% by weight of at least one polymeric agent selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase chan...
--------------------------------------------------------------------------------

A COMPOSITION INCLUDING A SILICONE-BASED POLYMER AND A METHOD OF TREATING SKIN DISORDERS USING THE COMPOSITION

(WO2007085086) 02.08.2007 C08L 83/04 KAILA, Sanjeev
A composition is formed by the step of feeding a molecule that has an active oxygen-forming species into a silicone-based polymer. The silicone-based polymer is substantially free of pendant groups that are reactive with active oxygen species. Silicone-based polymers have proven scar-healing properties. As such, the composition is useful for treating skin disorders, especially scars, to reduce the appearance of the scars. Furthermore, bacteria and infections may contribute to the formation of scars. The active oxygen-forming species form active oxygen species, which oxidize pathogens including bacteria, viruses, and fungus to sterilize an area in contact with the composition. As a result, the appearance of scars treated with the composition...
--------------------------------------------------------------------------------

SILICONE ADHESIVE FOR ADHESION TO WET SURFACES

(WO2007084266) 26.07.2007 None DOW CORNING CORPORATION
A silicone adhesive composition used for adhering a device or a substance to a wet surface contains (i) a silicone resin that is cohydrolysis product of a trialkyl hydrolyzable silane and an alkyl silicate in which the cohydrolysis product contains a plurality of silicon-bonded hydroxy groups; (ii) a linear organopolysiloxane fluid containing terminal silicon-bonded hydroxy groups having a viscosity above 200,000 mm2/s at 25oC; (iii) a trialkylsiloxy terminated polyorganosiloxane fluid having a viscosity of 100,000-600,000 mm2/s at 25oC; (iv) a water soluble muco-adhesive polymer selected from the group consisting of a poly(ethylene oxide) polymer having a molecular weight of 100,000 to 8,000,000, an acrylic acid polymer having a molecular ...
--------------------------------------------------------------------------------

STABLE THERAPEUTIC FORMULATIONS

(WO2007084247) 26.07.2007 A61K 48/00 ALZA CORPORATION
Compositions of and methods for formulating and delivering biologically active agent formulations having enhanced physical stability, and wherein deterioration from the presence of oxygen and/or water is minimized and/or controlled, to yield a stable formulation. The compositions of and methods for formulating and delivering biologically active agents of the present invention further facilitate their incorporation into a biocompatible coating which can be employed to coat a stratum-comeum piercing microprojection, or a plurality of stratum-corneum piercing microprojections of a delivery device, for delivery of the biocompatible coating through the skin of a subject, thus providing an effective means of delivering the biologically active age...
--------------------------------------------------------------------------------

USE OF GLUTEN FOR WOUND TREATMENT AS ACTIVE HEALING INGREDIENT

(WO2007084127) 26.07.2007 A61K 31/74 PETERS, Verdon
A treatment protocol for chronic wounds, such as ulcers, using gluten as the active treatment ingredient. A plant material containing gluten protein is processed to obtain a compound of at least 70% gluten protein. The processed gluten can be applied directly to the wound or combined with a base topical ointment or cream as the active component. The gluten comprises at least 2.5% of the topical ointment or cream by weight, or can be applied directly to the wound as 100% gluten. The gluten is applied at least twice per day. Conventional treatment of rinsing, cleaning, and debriding as required are maintained as well as follow-up monitoring of the patient by a physician at least twice per week until healed.
--------------------------------------------------------------------------------

C-KIT ACTIVATION INHIBITOR, SKIN WHITENING COMPOUND AND COMPOSITION FOR SKIN WHITENING CONTAINING THE SAME

(WO2007083904) 26.07.2007 A61K 8/49 LG HOUSEHOLD &HEALTH CARE LTD.
Disclosed are a c-Kit activation inhibitor, a skin whitening compound and a composition for skin whitening comprising the skin whitening compound as an active ingredient. The c-Kit activation inhibitor of the present invention is a flavone derivative selected from the group consisting of the compounds represented by Formulas 1 to 10. The flavone derivative inhibits activity of the c-Kit associated with melanin synthesis, melanocyte differentiation and maturity, etc. Accordingly, the above-mentioned flavone derivatives are useful as skin whitening compound, and the cosmetic compositions comprising the flavone derivatives as an active ingredient can be highly effectively used for skin whitening, for example treating melasma, freckles, etc.
--------------------------------------------------------------------------------

COSMETIC COMPOSITION CONTAINING EXTRACTS OF PINUS KORAIENSIS AS ACTIVE INGREDIENT

(WO2007083868) 26.07.2007 A61K 8/97 AMOREPACIFIC CORPORATION
The present invention relates to a cosmetic composition comprising extract of Pinus koraiensis and at least one selected from the group consisting ofextract of Primus mume, extract of Phaseolus angularis, extract of Chaenomeles sinensis and extract of Sesamum indicum, as an active ingredient. More particularly, the cosmetic composition according to the present invention comprises extract of Pinus koraiensis and at least one selected from the group consisting ofextract of Prunus mume, extract of Phaseolus angularis, extract of Chaenomeles sinensis and extract of Sesamum indicum, as an active ingredient to show the effect promoting the growth of keratinocyte, the effect eliminating oxygen free radicals, the effect promoting the biosynthesis o...
--------------------------------------------------------------------------------

USE OF CHAVICOL AS AN ANTISEPTIC

(WO2007082864) 26.07.2007 A61P 17/14 POLICHEM S.A.
Topical compositions comprising chavicol (p-allylpenol) are an efficient approach to the treatment of skin and scalp infected by pathogenic microorganisms such as yeast, fungi or bacteria. Chavicol, may be present in an amount which ranges from 0.1 to 10 % by weight of the composition which, on its turn, may be in the form of cream, lotion, mousse, spray, emulsion, shampoo or gel. The composition may further contain an additional active principle, together with the usual topically acceptable excipients.
--------------------------------------------------------------------------------

ANTIPERSPIRANT STICK COMPOSITIONS

(WO2007082063) 19.07.2007 A61K 8/02 UNILEVER PLC
Disclosed are antiperspirant stick compositions comprising specified amounts of antiperspirant active; carrier oil comprising volatile silicone oil and non-volatile masking oil; structurant comprising fatty alcohol and cosmetically acceptable wax having a melting point of 75 to 95C, a portion of wax comprises polyethylene in specified amounts. Also disclosed are methods of making such stick compositions, and methods of ameliorating perspiration by the topical application of such compositions to the skin.
--------------------------------------------------------------------------------

EXTRACT OF R. MIEHEI

(WO2007082001) 19.07.2007 A61K 8/97 ACTIVE ORGANICS, LP
Topical compositions comprising extracts of Rhizomucor miehei that are substantially devoid of acid-protease activity and their use in treating dermatologic conditions, including reducing the appearance of signs of skin aging.
--------------------------------------------------------------------------------

SKIN DISINFECTANT COMPOSITION AND METHODS FOR USING

(WO2007081404) 19.07.2007 A61K 8/43 SKINVISIBLE PHARMACEUTICALS, INC.
A skin disinfectant composition is provided according to the invention. The skin disinfectant composition comprises an effective amount of a disinfectant active component to provide disinfectant properties to skin tissue (esp. chlorhexidine or a salt thereof) , an effective amount of a skin bonding polymer component to hold the disinfectant active component to skin tissue so that the disinfectant active component becomes available on skin tissue to provide disinfectant properties (esp. a hydrophobic polymer/hydrophilic polymer adduct comprising a VP/alkylene copolymer, like VP/eicosene or VP/hexadecene copolymer, and water. A method of using a skin disinfectant composition is provided.
--------------------------------------------------------------------------------

NOVEL USE OF 1,2,3,4,6-PENTA-O-GALLOYL-BETA-D-GLUCOSE

(WO2007081190) 19.07.2007 A61K 31/35 BIO CLUE &SOLUTION CO., LTD.
The present invention relates to novel use of 1,2,3,4,6-penta-O-galloyl-beta-D-glucose. More particularly, the present invention relates to a pharmaceutical composition and cosmetic composition for preventing and treating skin disease, comprising 1,2,3,4,6-penta-O-galloyl-beta-D-glucose represented by formula 1 as an active ingredient.. Also, the invention relates to a method for preventing and treating skin disease using 1,2,3,4,6-penta-O-galloyl-beta-D-glucose, and to the use of 1 ,2,3 ,4,6-penta-O-galloyl-beta-D-glucose.
--------------------------------------------------------------------------------

HERBAL COMPOSITION

(WO2007080525) 19.07.2007 A61K 36/185 NICHOLAS PIRAMAL INDIA LTD
The present invention relates to a novel herbal composition comprising extract of leaves of Polyalthia longifolia and method of manufacture of said composition. The present invention relates to a herbal extract selectively comprising a compound 16- hydroxycleroda-3,13(14)-dien-15, 16-olide (compound 1), as a bioactive marker and optionally other active(s). The invention also discloses methods of administration of the said herbal composition for the treatment of various inflammatory disorders. Optionally the said extract may be combined with other bioactive substances to obtain a synergistic effect.
--------------------------------------------------------------------------------

NOVEL IMMUNOLOGICALLY ACTIVE PEPTIDE FRAGMENTS OF A PROLINE-RICH POLYPEPTIDE ISOLATED FROM COLOSTRAL MAMMALIAN FLUIDS FOR TREATMENT OF VIRAL AND NON-VIRAL DISEASES OR DISEASED CONDITIONS

(WO2007079052) 12.07.2007 A61K 39/00 KEECH, Andrew, Maurice
Present invention relates to an immunologically active nonapeptide fragments of a proline-rich polypeptide isolated from mammalian colostral fluids for treatment of viral and non-viral diseases or diseased conditions, a method and a system for processing mammalian colostral fluids for isolating target peptides and proteins, a pharmaceutical formulation containing such peptides and its use for the treatment of viral diseases or diseased conditions. The product comprises proline-rich polypeptide of immuno regulatory properties. The method of processing includes, steps of passing bodies fluids, such as, mammalian colostral fluids through at least one ion exchange column such as an anionic resin and/or a canonic resin. The ion exchange column c...
--------------------------------------------------------------------------------

FOAMING, COLOR-CHANGING TOPICAL COMPOSITION AND METHOD OF IMPARTING A COSMETIC EFFECT

(WO2007078460) 12.07.2007 A61K 8/19 AVON PRODUCTS, INC.
There is an anhydrous topical composition. The composition has a) an active ingredient; b) a base compound of a carbonate or bicarbonate salt of an alkali metal or an alkaline earth metal; c) an acid compound; and d) a cosmetically acceptable anhydrous vehicle. The base compound and the acid compound are reactable and are present in amounts sufficient to foam the topical composition when the topical composition is exposed to water. The topical composition changes color upon exposure to water. There is also a method for imparting a cosmetic effect to a topical surface.
--------------------------------------------------------------------------------

BORON-CONTAINING SMALL MOLECULES

(WO2007078340) 12.07.2007 A61K 31/69 ANACOR PHARMACEUTICALS, INC.
This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
--------------------------------------------------------------------------------

COSMETIC COMPOSITION COMPRISING GLAUCINE AND ITS USE

(WO2007077541) 12.07.2007 A61K 8/49 SEDERMA
The present invention concerns the use of glaucine or a plant extract containing it, as an active ingredient, alone or in association with at least another active ingredient usually used in cosmetic or dermopharmaceutical field, for the preparation of a cosmetic or dermopharmaceutical composition with a topical use for skin, integuments, and/or mucosas. The present invention relates also to the use of glaucine or a plant extract containing it as an agent inducing adipocyte reversion, for the preparation of cosmetic or dermopharmaceutical compositions especially against cellulitis, orange peel and fat deposits.
--------------------------------------------------------------------------------

SYNERGISTIC ACTIVE PREPARATIONS COMPRISING DIPHENYLMETHANE DERIVATIVES AND FURTHER SKIN AND/OR HAIR LIGHTENING AND/OR SENILE KERATOSIS REDUCING COMPOUNDS

(WO2007077259) 12.07.2007 A61K 8/34 SYMRISE GMBH &CO. KG
The present invention relates to specific synergistic active skin- and/or hairlightening and/or senile keratosis-reducing (cosmetic or pharmaceutical) preparations comprising a mixture comprising a mixture comprising or consisting of a) a tyrosinase-inhibiting amount of one or more compounds of the formula (I): and b) a skin- and/or hair lightening and/or senile keratosis-reducing amount of one or more compounds selected from the group consisting of (i) chelating agents, (ii) phenolic derivatives, plant extracts with an amount of phenolic derivatives and (iii) organic acid derivatives as well as uses thereof.
--------------------------------------------------------------------------------

UV-RADIATION PROTECTANT COMPOSITIONS

(WO2007075747) 05.07.2007 None SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC.
A substantially aqueous composition comprising one or more particle encapsulated sunscreen active agents, at least one volatile additive, and at least one UV-radiation scattering agent, whereby the composition provides an SPF greater than 30.
--------------------------------------------------------------------------------

KIT AND COMPOSITION OF IMIDAZOLE WITH ENHANCED BIOAVAILABILITY

(WO2007072216) 28.06.2007 None FOAMIX LTD.
A composition and therapeutic kit provide a therapeutic azole with increased solubility. The kit includes an aerosol packaging assembly containing a container accommodating a pressurized product and an outlet capable of releasing the pressurized product as a foam. The pressurized product includes a foamable composition including: i. a therapeutic azole, wherein the solubility of the azole in the composition before foaming is less than the solubility of the azole in the composition after foaming; ii. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a co-solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight; iii. a surface-active agent; iv. about 0.01...
--------------------------------------------------------------------------------

COMPOSITION CONTAINING AND ACTIVE AGENT AND POLYMERIC CARRIER PARTICLES COMPRISING A COPOLYMER OF A HYDROPHOBIC MONOMER AND A HYDROPHILIC POLYSACCHARIDE

(WO2007071325) 28.06.2007 A61K 9/16 UNILEVER PLC
A composition s provided comprising: a) polymeric particles comprising a copolymer of a hydrophobic monomer and a hydrophilic Polysaccharide; b) a pharmaceutical and/or skin and/or hair and/or laundry active residing within and/or on the surface of the polymeric particles; and c) a pharmaceutically and/or cosmetically acceptable vehicle within which the polymeric particles are dispersed. The composition shows improved target specificity for skin, hair and silk fibres, synthetic fibres (including nylon and polyester) for delivery of pharmaceutical and/or skin and/or hair and/or laundry actives.
--------------------------------------------------------------------------------

TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS

(WO2007070983) 28.06.2007 A61K 38/28 APOLLO LIFE SCIENCES LIMITED
The present invention generally relates to a vehicle useful for delivering a pharmaceutically active compound including a genetic molecule or composition. More particularly, the present invention provides microemulsions for transdermal delivery of pharmaceutically active agents to a subject.
--------------------------------------------------------------------------------

COSMETIC COMPOSITIONS WITH ENCAPSULATED PIGMENTS AND A METHOD FOR USING

(WO2007070168) 21.06.2007 A61K 9/00 AVON PRODUCTS, INC.
There is a pigmented cosmetic composition. The composition has a cosmetically acceptable vehicle, a cosmetic active, and a plurality of encapsulated pigment particles. The particles have an encapsulant and an entrapped pigment within the encapsulant. The encapsulant has silicon dioxide and exhibits a refractive index of about 1.4 to about 1.6.
--------------------------------------------------------------------------------

METHODS FOR CULTURING MESENCHYMAL STEM CELL AND COMPOSITIONS COMPRISING MESENCHYMAL STEM CELL FOR REPARING SKIN DEFECTS

(WO2007069813) 21.06.2007 C12N 5/08 MODERN CELL &TISSUE TECHNOLOGIES INC.
The present invention relates to a method for culturing a mesenchymal stem cell highly expressing collagen, which comprises the steps of: (a) culturing a mesenchymal stem cell isolated from an adipose tissue in a serum-containing medium; and (b) culturing the mesenchymal stem cell in a serum-free medium, wherein the expression level of type I pro-collagen of the mesenchymal stem cell cultured in the step (b) is higher than that of fibroblast and the expression level of pro-MMP-1 (pro-matrix metalloprotease-1) of the mesenchymal stem cell cultured in the step (b) is lower than that of fibroblast. In addition, the present invention relates to a pharmaceutical composition for repairing a skin defect comprising mesenchymal stem cells as active ...
--------------------------------------------------------------------------------

INSECTICIDAL COMPOSITION CONTAINING BORIC ACID

(WO2007069796) 21.06.2007 A01N 25/02 CHEPKONGA, Anna, Vansilievna
An insecticidal composition comprising boric acid 35-38%, petroleum jelly 24-29%, water 7-10%, glycerin 7.5-9.5%, sugar 7-10%, garlic powder 1-2.5%, The formulation that carries the active ingredient is comprised of an active ingredient, a emulsifying agent, a gelling agent, antifoaming agent, a moisturing agent, and a flavoring agent.
--------------------------------------------------------------------------------

EMULSION-CONTAINING MEDICAL ARTICLES

(WO2007068086) 21.06.2007 A61L 15/32 BIOARTIFICIAL GEL TECHNOLOGIES INC.
Disclosed are oil-in- water emulsion gels comprising a hydrogel matrix, a gel-forming hydrophilic polymer covalently crosslinking a protein, with a hydrophobic phase dispersed therein. The hydrophobic phase optionally contains a biologically active agent, and is preferably an omega-3 oil. The gels can be used as drug delivery devices or preferably wound dressings Also disclosed are methods for making said emulsion gels
--------------------------------------------------------------------------------

TOPICAL FILM COMPOSITIONS FOR DELIVERY OF ACTIVES

(WO2007067494) 14.06.2007 A61K 8/02 MONOSOLRX, LLC
The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain a topical active agent.
--------------------------------------------------------------------------------

TRANSDERMAL ADMINISTRATION OF ACTIVE AGENTS FOR SYSTEMIC EFFECT

(WO2007066150) 14.06.2007 A61K 47/36 PHARMAKODEX LTD
The present invention relates to compositions for transdermal administration of a therapeutic agent for providing a systemic therapeutic effect. In particular, the invention relates to spreadable compositions, or compositions which may be solid at a temperature of about 25C or less and have a softening point of not higher than 35C, wherein transdermal administration of the therapeutic agent may be either rapid or sustained.
--------------------------------------------------------------------------------

A METHOD FOR OBTAINING A BIOLOGICALLY ACTIVE FRACTION OF BLOOD SERUM TREATED WITH GAMMA IRRADIATION AND THE USE THEREOF

(WO2007065714) 14.06.2007 A61K 35/16 OWEN HOLDING LTD.
The present invention relates to a method for preparing a biological active fraction of blood serum, the biological active fraction (S-I-10) and a pharmaceutical composition comprising said fraction as well as uses thereof in the treatment of various diseases and conditions, in particular seizures, cardiovascular diseases and proliferative diseases.
--------------------------------------------------------------------------------

AN APPLICATOR CARTRIDGE FOR AN ELECTROKINETIC DELIVERY SYSTEM FOR SELF ADMINISTRATION OF MEDICAMENTS

(WO2007064722) 07.06.2007 A61N 1/30 TRANSPORT PHARMACEUTICALS, INC.
An applicator for a device for electrokinetic delivery of medicament to a treatment site includes an applicator head having an active electrode, a matrix, and a medicament or a medicament and an electrically conductive carrier, carried by the matrix in electrical contact with the electrode. The cartridge includes a plurality of raised projections allowing the matrix and head to be ultrasonically welded one to the other. The electrode opens through a face of the head remote from the matrix for connection with an electrical connector carried by the device. A lid overlies the matrix and is releasably attached to a margin of the head. The lid includes layers of different materials with one of the layers formed of a metallic material having a di...
--------------------------------------------------------------------------------

BLACKBERRY LEAF EXTRACT AS AN ACTIVE INGREDIENT AGAINST SKIN IRRITATIONS AND INFLAMMATIONS

(WO2007063087) 07.06.2007 A61K 36/73 SYMRISE GMBH &CO. KG
The present invention concerns the field of plant extracts and their uses, in particular for cosmetic, oral hygiene and pharmaceutical purposes. In particular the invention concerns blackberry leaf extracts and preparations and medicaments containing them, as well as their use to inhibit irritating and inflammatory skin conditions.
--------------------------------------------------------------------------------

PATCH

(WO2007062435) 31.05.2007 A61K 9/70 NAMIBIA MEDICAL INVESTMENTS (PTY) LTD
The invention provides a patch device adapted for use in the transdermal administration to a patient of a composition including one or more pharmaceutically, cosmetically, pesticidally, prophylactically, and nutritionally active substance, the patch consisting of a layered construct adapted to be adhered to the skin of a patient and defining a cavity for receiving one or more disruptable containers of the composition or components of the composition to be administered between a proximal layer and a distal layer thereof, which proximal layer is adapted in use to be located in intimate contact with the skin of the patient and which distal layer is in use disposed on the outer side thereof , wherein the proximal layer is partially permeable to...
--------------------------------------------------------------------------------

COMPOSITION FOR HAIR GROWTH PROMOTION CONTAINING VITAMIN B AND PYRIMIDINE OXIDE DERIVATIVES

(WO2007061169) 31.05.2007 A61K 8/67 AMOREPACIFIC CORPORATION
Disclosed is a hair growth-promoting composition containing water- soluble B-group vitamins and pyrimidine oxide derivatives. More particularly, the hair growth-promoting composition contains, as active ingredients, B-group vitamins and pyrimidine oxide derivatives, and thus directly induces hair growth by promoting the transition from the telogen phase to the anagen phase through the vasodilation of blood vessels around hair follicles.
--------------------------------------------------------------------------------

PHARMACEUTICAL COMPOSITIONS FOR CELL THERAPY OF PIGMENTATION DISORDERS

(WO2007061168) 31.05.2007 A61K 38/17 Modern Cell &Tissue Technologies Inc.
The present invention relates to a pharmaceutical composition for cell therapy of pigmentation disorders, which comprises as an active ingredient (a) melanocytes and keratinocytes, or (b) melanocytes and fibroblasts. The cell therapy composition of this invention allows for the first time to treat pigmentation disorders through cell therapy regimen. The present composition comprises as active ingredients a mixed cell preparation of melanocytes and keratinocytes or a mixed cell preparation of melanocytes and fibroblasts such that it induces very effectively pigmentation to treat diseases associated with hypopig mentation such as vitiligo.
--------------------------------------------------------------------------------

COMPOSITIONS CONTAINING TOPICAL ACTIVE AGENTS AND PENTYLENE GLYCOL

(WO2007060512) 31.05.2007 A61K 8/63 L'ORAL
Disclosed are cosmetic and dermatological compositions containing hydrocortisone or a derivative thereof, a glycol and a thickening or gelling agent, and methods of making and using them.
--------------------------------------------------------------------------------

HIGH SUNSCREEN EFFICIENCY WATER-IN-OIL EMULSION

(WO2007059091) 24.05.2007 A61K 8/893 TANNING RESEARCH LABORATORIES, INC.
The present invention relates to highly stable water-in-oil sunscreen emulsions that provide a high sunscreen efficiency ('SE') having a sun protection factor ('SPF') of X, where X is at least about 15, and having a sunscreen efficiency ('SE') of at least 2, preferably at least 3, where SE is the ratio of SPF over the total weight percentage of sunscreen actives based on the total weight of the composition. The emulsions of the present invention provide photoprotection for the period corresponding to the labeled SPF throughout the period of exposure to natural sunlight and comprises (i) at least one sunscreen active and (ii) an alkyl dimethicone copolyol emulsifier in which the water-soluble, alkyl-soluble and silicone-soluble groups of the...
--------------------------------------------------------------------------------

ANTIPERSPIRANT/DEODORANT COMPOSITIONS

(WO2007058735) 24.05.2007 A61K 8/81 EXXONMOBIL CHEMICAL PATENTS INC.
Disclosed herein is a composition for topical application to human skin, comprising a biologically active material and a cosmetically suitable carrier, wherein the cosmetically suitable carrier comprises 5-95 wt% of a mixed feed polyolefin based on the total weight of the composition, wherein the mixed feed polyolefin comprises two or more C6-C20 copolymerized monomers, and wherein at least two of the copolymerized monomers are each present in the mixed feed polyolefin at 10 wt% or more, based on the total weight of the mixed feed polyolefin. A method of making a composition for topical application to human skin is also disclosed.
--------------------------------------------------------------------------------

TREATMENT OF CHRONIC KIDNEY DISEASE (CKD) SUBJECTS USING LANTHANUM COMPOUNDS

(WO2007056721) 18.05.2007 A61K 33/24 SHIRE INTERNATIONAL LICENSING B.V
A subject with symptoms of chronic kidney disease (CKD), who does not have end-stage renal disease (ESRD), can be treated by orally administering a pharmaceutical composition as an active ingredient a therapeutically effective amount of a non-toxic lanthanum compound. Administration of a lanthanum compound can prevent the progression of CKD, treat soft tissue calcification, and treat secondary hyperparathyroidism.
--------------------------------------------------------------------------------

FILM-FORMING RESINS AS A CARRIER FOR TOPICAL APPLICATION OF PHARMACOLOGICALLY ACTIVE AGENTS

(WO2007056491) 18.05.2007 A61K 31/4178 JALEVA, LLC
The invention provides a biological dressing for treatment of a dermatological disease comprised of one or more resins or other film-forming agents, a topically acceptable volatile solvent, and a pharmacologically active agent. The combined one or more resins are present in a suitable amount such that the composition, when the solvent evaporates, will dry to form a solid coating that sticks to the skin, nail or mucosal membrane to which the composition is applied, and maintain the pharmacologically active agent over a sustained period of time in contact with sites on the skin or mucosal membranes exhibiting symptoms of the disease. Methods are provided for treating symptoms of dermatological diseases with such a pharmacological composition.
--------------------------------------------------------------------------------

PROTEIN COMPOSITION FOR PROMOTING WOUND HEALING AND SKIN REGENERATION

(WO2007055760) 18.05.2007 A61K 38/46 ESSENTIAL SKINCARE, LLC
Methods and regimens for stimulating proliferation and inhibiting death of skin cells in wounded, non-wounded healthy and unhealthy, or transplanted skin and skin cell suspensions are provided. The methods and regimens include a step of administering to an area of host skin and/or transplanted skin a combination of lactoferrin and alkaline phosphatase such as placental alkaline phosphatase. The active components may be administered topically, by injection, or by other suitable means. In addition to improving the quality of skin, the reported methods may also be effective to reduce inflammation and microbial infection in the skin. Embodiments of the invention also provide compositions suitable for use in the described methods.
--------------------------------------------------------------------------------

FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF

(WO2007054818) 18.05.2007 None FOAMIX LTD.
A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
--------------------------------------------------------------------------------

SUBSTRATE AND PERSONAL-CARE APPLIANCE FOR HEALTH, HYGIENE, AND/OR ENVIRONMENTAL APPLICATION(S); AND METHOD OF MAKING SAID SUBSTRATE AND PERSONAL-CARE APPLIANCE

(WO2007053756) 10.05.2007 A47K 7/03 KIMBERLY-CLARK WORLDWIDE, INC.
Substrates, and personal-care appliances made from such substrates, include an inter-bonded fibrous layer having shaped discontinuities and reinforcing strands attached to said inter-bonded fibrous layer. Pores between the fibers in the inter-bonded fibrous layer are suited to help hold liquid. The shaped discontinuities are suited to help generate suds or lather should the substrate or personal-care appliance be used in combination with a cleaning composition, soap formulation, or other such material having a surface-active agent or other chemical or compound that helps generate lather. The reinforcing strands help strengthen, or improve the wet resilience of, the inter-bonded fibrous layer. Furthermore, by selecting the appropriate ingred...
--------------------------------------------------------------------------------

COSMETIC SKINCARE APPLICATIONS EMPLOYING MINERAL-DERIVED TUBULES FOR CONTROLLED RELEASE

(WO2007053647) 10.05.2007 A61K 9/20 NATURALNANO, INC.
Compositions and methods pertaining to the topical treatment of skin are disclosed. The present invention relates to topical compositions for regulating the condition of skin, especially for regulating visible and/or tactile discontinuities in skin associated with skin aging, environmental affects and the like. One embodiment of the present invention relates to improving skin with compositions containing one or more non-volatile, slowly absorbed, liquid or semi-liquid organic substances (active agents) via controlled release of active agents associated with mineral-derived tubules such as halloysite nanotubules. For example, the active agents, in the form of organic substances may include vitamin compounds and glycerin, among others.
--------------------------------------------------------------------------------

PERSONAL CARE COMPOSITION

(WO2007052230) 10.05.2007 A61K 8/03 THE PROCTER &GAMBLE COMPANY
Personal care composition comprising from about 5% to about 75% of an oil phase; an aqueous phase; from about 0.1% to about 2% of a polymeric thickener; and a skin care active; wherein said composition comprises at least two separate phases, and after agitation and dispensation from a suitable container containing a suitable propellant, forms stable foam.
--------------------------------------------------------------------------------

MULTI-PHASE PERSONAL CARE COMPOSITION COMPRISING A STABILIZING PERFUME COMPOSITION

(WO2007052224) 10.05.2007 None THE PROCTER &GAMBLE COMPANY
A method of stabilizing a multiphase composition is described. The composition comprises a structured surfactant phase, a benefit phase and a perfume comprising perfume raw materials. The method comprises a step of selecting at least 70% of the perfume raw materials that have a ClogP of greater than 1.8.
--------------------------------------------------------------------------------

TOPICAL PHARMACEUTICAL FOAM COMPOSITION

(WO2007050543) 03.05.2007 A61K 9/00 COLLEGIUM PHARMACEUTICAL, INC.
A stable topical alcohol-free aerosol foam containing one or more keratolytic agents is provided. The foam-forming formulation is an emulsion which contains an HFA propellant and one or more keratolytic agents. The emulsion has an oil phase and an aqueous, i.e. water-containing, phase. The active agent(s) may be present in either phase of the emulsion or dispersed in the emulsion. The oil phase may consist at least in part of the HFA propellant. Either or both of the oil phase and the aqueous phase may contain one or more surfactants, emulsifiers, emulsion stabilizers, buffers, and/or other excipients. The foam is stable on the skin, for example, for at least 5 minutes at body temperature, preferably at least 20 minutes at body temperature,...
--------------------------------------------------------------------------------

NON-IRRITATING FORMULATION AND METHOD FOR THE INTRADERMAL DELIVERY OF SUBSTANCES

(WO2007050127) 03.05.2007 A61K 9/14 SCHUR, Henry, B.
This invention describes a composition of matter to facilitate intra-dermal delivery of a great variety of active substances, especially including high molecular weight cosmeceuticals . Also disclosed is a method of forming the composition of matter and applying topically to patients, especially using a cream or patch. The active substance is initially combined with a biopolymer, which combination, is subsequently linked to a base formulation whereby the base formulation aids in the intra-dermal delivery of the active substance without the skin irritation limitations of other formulations and dermal transmitting methods. The use of a combination of natural herbal, vegetable and animal products combined in this invention with biopolymers per...
--------------------------------------------------------------------------------

PEPTIDES EXHIBITING EFFICACIES OF IMPROVEMENT IN SKIN CONDITIONS OR TREATMENT OF PERIODENTAL DISEASES

(WO2007049904) 03.05.2007 C07K 14/50 CAREGEN CO., LTD
The present invention relates to a composition for improving a skin condition or treating a periodontal disease, which comprises as an active ingredient a basic fibroblast growth factor-derived peptide. The peptides of this invention exhibit superior efficacies and much better stability and skin permeation than natural- occurring bFGF. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on improvement in skin conditions and treatment of periodontal diseases. In addition, the peptides of this invention can be advantageously applied to pharmaceutical compositions, cosmetics, toothpaste and compositions for mouth cleaning and caring.
--------------------------------------------------------------------------------

PROTECTION OF OXIDIZABLE AGENTS

(WO2007048645) 03.05.2007 None CIBA SPECIALTY CHEMICALS HOLDING INC.
Formulations for cosmetical or pharmaceutical use contain an antioxidant in encapsulated form and a cosmetically or pharmaceutically acceptable carrier. The antioxidant is selected from carbon bridged hindered phenoles, ester bridged hindered phenoles, amide bridged hindered phenoles, lactones of hindered phenoles, sterically hindered oxylamines and sterically hindered hydroxylamines. The encapsulated antioxidant is of high activity and suitable to protect a further active ingredient, e.g. oxidizable natural substances, vitamins, fragrances, and extracts from plants fungi, algae or animals, from premature degradation, especially when coencapsulated together with the ingredient. The formulations are useful inter alia for the preparation of a...
--------------------------------------------------------------------------------

CATIONIC POLYMER NANOPARTICLES ENCAPSULATING AN ACTIVE INGREDIENTS, AND THE COSMETIC COMPOSITION CONTAINING THE SAME

(WO2007046632) 26.04.2007 A61K 8/11 AMOREPACIFIC CORPORATION
Disclosed herein are cationic polymer nanocapsules encapsulating an oil- soluble active ingredient, and a cosmetic composition containing the same. The cationic polymer nanocapsules have a molecular weight of 5,000-100,000, a surface potential of 5-100 mV and a particle size of 50-500 nm. Also, disclosed is a cosmetic composition containing said cationic polymer nanocapsules.
--------------------------------------------------------------------------------

HYALURONIDASE INHIBITOR CONTAINING POLY-GAMMA- GLUTAMIC ACID AS AN EFFECTIVE COMPONENT

(WO2007046569) 26.04.2007 A61K 8/00 BIOLEADERS CORPORATION
The present invention relates to a hyaluronidase inhibitor containing poly-gamma- glutamic acid (PGA) as an active ingredient, a composition for maintaining skin elasticity and a composition for improving allergy, wherein each, of the compositions contains PGA as an active ingredient. The inventive compositions containing PGA are effective in maintaining skin moisturization and skin elasticity by effectively inhibiting the activity of hyaluronidase which is an enzyme that degrades hyaluronic acid present in the skin dermis. Also, the compositions can relieve allergic symptoms by inhibiting the permeability of inflammatory cells.
--------------------------------------------------------------------------------

TOPICAL COMPOSITIONS FOR THE TREATMENT OF DEPILATION-INDUCED SKIN IRRITATION OR PREVENTION THEREOF

(WO2007046097) 26.04.2007 H01L 31/0264 MEDIDERMIS LTD.
The present invention relates to topical compositions comprising as active ingredients Aluminium Chloride and Sulfur for treatment of skin irritation induced by depilation. Said compositions have pharmaceutical and/or cosmetic and/or quasi cosmetic properties. The present invention also involves methods of making and methods of using such compositions. Furthermore, the present invention consists of a method for prevention and/or treatment of skin irritation induced by depilation.
--------------------------------------------------------------------------------

BANDAGE

(WO2007046081) 26.04.2007 A61H 23/02 PRIZANT, Eran Izhak
Sticky bandage (SB) for a topical treatment provides for massaging while applying cosmetic agents or drugs to a skin of a user. The SB includes a vibrating member and a layered SB base. The SB is electrically powered either by an internal battery or from an external source. The proximal layer (that is closer to the skin) of the SB base, which is optionally replaceable, includes the active substances. The vibrating member consists of either piezoelectric ceramics, arrays of electromagnets, or miniature electric motor and programmable activation logic. Optionally the battery or the connector providing for electrical powering and an activation switch are installed in a separate housing that is electrically connected to the SB. An electrical sa...
--------------------------------------------------------------------------------

CELL-FREE PROTEIN EXPRESSION SYSTEMS AND METHODS OF USE THEREOF

(WO2007044894) 19.04.2007 C12N 9/12 CHEMBRIDGE RESEARCH LABORATORIES, INC.
Provided herein are in vitro (cell-free) protein translation (IVT) systems for the expression of kinases. In particular, provided herein is an IVT system for the expression of a panel of protein tyrosine kinases (PTK), (e.g., receptor protein tyrosine kinases (RTK) and/or cytoplasmic tyrosine kinases (CTK)), and/or fragments thereof (e.g., kinase domains and/or active fragments thereof).
--------------------------------------------------------------------------------

COMPOSITIONS FOR IMPROVING SKIN CONDITIONS COMPRISING HUMAN GROWTH HORMONES AS AN ACTIVE INGREDIENT

(WO2007043721) 19.04.2007 A61K 8/00 Regeron, Inc.
Disclosed herein is a skin condition-improving composition for topical application to the skin, comprising human growth hormone as an active ingredient, and a method for improving skin conditions using the same. The disclosed composition exhibits various skin conditioning effects, such as acne treatment, wrinkle improvement, dark spot removal, skin elasticity improvement, hair growth stimulation, skin aging prevention, skin moisturization and the proliferation of skin epidermal stem cells.
--------------------------------------------------------------------------------

COMPOSITION FOR REGULATION OF MAMMALIAN KERATINOUS TISSUE

(WO2007041548) 12.04.2007 A61K 8/34 THE PROCTER &GAMBLE COMPANY
Personal care compositions comprising skin and/or hair care actives. Such compositions are useful for regulating the condition of mammalian keratinous tissue needing such treatments, particularly skin lightening. There is provided a personal care composition comprising a safe and effective amount of a first active selected from the group consisting of octadecenedioic acid, methyl sulfonyl methane, an avenythramide compound and combinations thereof .
--------------------------------------------------------------------------------

COMPOSITIONS COMPRISING HYPSIZYGUS ULMARIUS EXTRACT

(WO2007041327) 12.04.2007 A61K 36/07 CHEN, Chia
Disclosed are topical compositions comprising extracts of Hypsizygus ulmarius in amounts that are effective to influence LTB4-mediated chemotaxis and/or IL-1 mediated adhesion of polymorphonuclear leukocytes. The hypsizygus ulmarius extract may be used alone or in combination with secondary anti-inflammatory and skin active agents, such as other mushroom and/or natural extracts. The secondary anti-inflammatory agents may or may not function by antagonizing LTB4-mediated chemotaxis and IL-1 mediated adhesion. The extract may be incorporated into a cosmetically acceptable vehicle. The present invention includes methods of treating skin inflammation by applying to inflamed skin, anti-inflammatory effective amounts of Hypsizygus ulmar...
--------------------------------------------------------------------------------

SACCHARIDE FOAMABLE COMPOSITIONS

(WO2007039825) 12.04.2007 None FOAMIX LTD.
A foamable composition, containing a saccharide for use in the treatment of various disorders including: water, a saccharide, about 0.2% to about 5% by weight of a surface- active agent, about 0.01% to about 5% by weight of at least one polymeric agent selected from a bio-adhesive agent, a gelling agent, a film forming agent and a phase change agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
--------------------------------------------------------------------------------

ANTIFUNGAL COMPOSITION

(WO2007039533) 12.04.2007 A61K 9/70 NOVARTIS AG
The invention provides a topical liquid antifungal composition containing an antifungal agent, a film-forming agent and a solvent. The composition is applied on the infected skin area to form a film that delivers the active agent. The invention also provides a method for treating a fungal infection on the skin by applying the topical antifungal composition that forms a film on the skin.
--------------------------------------------------------------------------------

PEPTIDE NUCLEIC ACID BASED GUANIDINIUM COMPOUNDS

(WO2007038171) 05.04.2007 A61K 47/48 NITTO DENKO CORPORATION
Disclosed herein are transmembrane transporter compounds containing guanidinium groups to enhance transport of a polymer backbone across biomembranes. Therapeutic and other biologically active moieties may be attached to the compounds. The polymer backbone may include peptide nucleic acid monomer units.
--------------------------------------------------------------------------------

HERBAL COMPOSITION FOR INFLAMMATORY DISORDERS

(WO2007036900) 05.04.2007 A61K 36/28 NICHOLAS PIRAMAL INDIA LTD
This invention relates to a novel herbal composition comprising an extract of flowering and fruiting heads of the plant, Sphaeranthus indicus. The said extract of Sphaeranthus indicus contains a compound, 3a-hydroxy-5a,9-dimethyl-3- methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1 ,2-b]furan-2-one (7- Hydroxy-4,1 1 (13)-eudesmadien-12,6-olide) (compound 1 ), as a bioactive marker. The invention also relates to a composition comprising 3a-hydroxy-5a,9-dimethyl- 3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1 ,2-b]furan-2-one (compound 1 ) as an active ingredient. The invention also relates to methods of manufacture of the said compositions. The invention also relates to methods of administration of the said compositions to a subject...
--------------------------------------------------------------------------------

ELECTROKINETIC DELIVERY SYSTEM AND METHODS THEREFOR

(WO2007035710) 29.03.2007 A61B 17/20 TRANSPORT PHARMACEUTICALS, INC.
The electrokinetic medicament delivery system includes at least one applicator having a multiplicity of non-conductive micro-needles carried on a non-conductive surface of the applicator. The opposite surface is formed of electrically conductive material for contact with an active electrode. The applicator includes a matrix containing a medicament or a carrier therefor between the opposite surfaces. When the applicator is applied to the individual's skin with the micro-needles penetrating the skin, an electrical current is completed through the power source, the active electrode, medicament, or electrically conductive carrier therefor, the targeted treatment site, the individual's body, a ground electrode and the power supply, thereby elect...
--------------------------------------------------------------------------------

THERAPEUTIC COMPOSITIONS COMPRISING CHORIONIC GONADOTROPINS AND HMG COA REDUCTASE INHIBITORS

(WO2007035395) 29.03.2007 A61K 31/401 VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROPERTY FOUNDATION
The invention provides improved methods and compositions for the treatment of cancer in a subject comprising administering to said subject a therapeutically effective amount of a composition comprising a chorionic gonadotropin or a therapeutically active fragment or analogue thereof in combination with an HMG CoA reductase inhibitor. The compositions and methods may also comprise geranylgeranyltransferase inhibitors (GGTI) and farnesyltransferase inhibitors (FTI) instead of or in addition to the HMG CoA reductase inhibitors of the invention.
--------------------------------------------------------------------------------

COMPOSITION FOR SKIN EXTERNAL APPLICATION CONTAINING GALLOCATECHIN GALLATE FOR MOISTURIZING EFFECT ON THE SKIN

(WO2007032624) 22.03.2007 A61K 8/49 AMOREPACIFIC CORPORATION
The present invention relates to a composition for external skin application having a skin-moisturizing effect, which comprises gallocatechin gallate as an active ingredient. More particularly, the composition for external skin application comprises gallocatechin gallate as an active ingredient to activate peroxisome proliferator activated receptor isoform alpha (PPAR-a), to stimulate expression of filaggrin and involucrin that are skin-moisturizing factors, and thus to provide excellent anti-drying and skin-moisturizing effects. More particularly, the composition for external skin application may further comprise theobromine and quercetin in addition to gallocatechin gallate to maximize such effects.
--------------------------------------------------------------------------------

IMPROVEMENTS IN OR RELATIMG TO COSMETIC COMPOSITIONS

(WO2007031793) 22.03.2007 A61Q 9/04 RECKITT &BENCKISER (UK) LIMITED
The present invention relates to a solid cosmetic composition which includes a soap and/or a non-soap surfactant, a hair modification active and/or skin enhancing agent, and at least one silicone and/or minera oil.
--------------------------------------------------------------------------------

COMPOSITION OF SKIN EXTERNAL APPLICATION FOR ANTI-AGING

(WO2007029982) 15.03.2007 A61K 8/49 AMOREPACIFIC CORPORATION
The present invention relates to an anti-aging composition for external use on skin, and more particularly, to an anti-aging composition for external use on skin comprising at least one of catechins and flavonols as an active ingredient to inhibit decomposition and promote generation or protection at the dermis-epidermis junction.
--------------------------------------------------------------------------------

USE OF PROTOBERBERINES AS AN ACTIVE SUBSTANCE REGULATING THE PILOSEBACEOUS UNIT

(WO2007029187) 15.03.2007 A61P 17/10 SEDERMA
The present invention relates to cosmetic use, by topic application on the skin of at least one protoberberine, with exception of berberine, or a vegetable extract containing it, as an active substance reducing activity of the pilosebaceous unit, preferably inhibiting activity of the pilosebaceous unit. In particular, the invention relates to cosmetic use of at least one protoberberine, with exception of berberine, or a vegetable extract containing it, as an agent reducing, preferably inhibiting the growth of hairs of the face and/or the body, and/or seborrheic activity of the sebaceous glands. The invention also relates to a cosmetic composition comprising in a dermatologically acceptable carrier, at least one protoberberine, with exceptio...
--------------------------------------------------------------------------------

A STRETCH ACTIVATED ARTICLE FOR DELIVERING VARIOUS COMPOSITIONS OR FUNCTIONAL ELEMENTS

(WO2007027260) 08.03.2007 B32B 3/00 KIMBERLY-CLARK WORLDWIDE, INC.
A stretch activated disposable article, such as a wipe or mitt, includes an upper material layer, and a lower material layer joined to the upper material layer such that a space is defined between the material layers. A functional element, for example a fluid composition, is stored in the space between the upper and lower material layers and becomes functional upon being exposed through the upper material layer with use of the article. The upper material layer includes a plurality of materially weakened positions along the surface thereof that are configured to part or separate upon stretching of the upper material layer to expose the functional element through the upper material layer.
--------------------------------------------------------------------------------

ORAL COMPOSITION FOR MOISTURISING SKIN

(WO2007027092) 08.03.2007 A61P 17/18 CAMPINA NEDERLAND HOLDING B.V.
Moisture of the skin, skin lipid balance and skin smoothness can be improved by administering an oral composition containing, as active ingredients, proteins and/or protein hydrolysates wherein the total proteins and hydrolysates contain at least 2 wt.% of cysteine residues. Preferably, the hydrolysates have an average molecular weight of between 200 and 4000 Dalton. The composition is administered in such an amount that between 25 and 500 mg of cysteine per day is supplied.
--------------------------------------------------------------------------------

A PHARMACEUTICAL COMPOSITION CONTAINING AN EXTRACT OF A MEDICINAL HERB BELONGING TO THE ORDER OF VIOLALES

(WO2007026185) 08.03.2007 A61K 36/86 ELS MAGYAR BIODROG KUTAT S FEJLESZT KFT.
An extract of a part of a medicinal herb belonging to the order of Violales, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient is used for enhancing the mitochondrial genesis thereby strengthening the organism of a mammal or for the prevention or treatment of diseases deriving from mitochondrial damage and/or reduced function of the constitutive nitric oxid synthase enzyme.
--------------------------------------------------------------------------------

A PHARMACEUTICAL COMPOSITION CONTAINING AN EXTRACT OF A SOLIDAGO SPECIES

(WO2007026184) 08.03.2007 A61K 36/28 ELSO MAGYAR BIODROG KUTAT S FEJLESZTO KFT
An extract of a part of a Solidago species, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient is used for enhancing the mitochondrial genesis thereby strengthening the organism of a mammal or for the prevention or treatment of diseases deriving from mitochondrial damage and/or reduced function of the constitutive nitric oxid synthase enzyme.
--------------------------------------------------------------------------------

TRANSDERMAL ACTIVE PRINCIPLE DELIVERY MEANS

(WO2007026124) 08.03.2007 A61K 9/06 HENDERSON MORLEY PLC
A transdermal active principle delivery means comprises a skin adherent or otherwise skin - tolerant substrate applicable to a skin, area affected by DNA virus, which substrate includes a composition for treating DNA comprising a transdermally effective carrier medium including at least one active principle selected from the group consisting of diuretic agents and/or cardiac glycoside agents.
--------------------------------------------------------------------------------

TOPICAL TANNING COMPOSITION CONTAINING MEDICATION

(WO2007025264) 01.03.2007 A61K 36/906 SPRAY TANNING, INC.
A topical, artificial skin tanning composition comprises a mixture of a tanning substance which darkens a person's skin and a medication which is active on and/ or absorbable by such person's skin. The tanning substance may be dihydroxyacetone, the medication may be turmeric, and the mixture is one which may be sprayed or otherwise applied directly to a person's skin. Any objectionable color of the medication is masked by the tanning substance.
--------------------------------------------------------------------------------

OXAZOLIDINONES BEARING ANTIMICROBIAL ACTIVITY COMPOSITION AND METHODS OF PREPARATION

(WO2007023507) 01.03.2007 C07D 413/14 SINDKHEDKAR, Milind, D.
The present invention provides compounds of Formula (I) having antimicrobial activity for preventing and treating diseases caused by microbial infections. Thus, the present invention provides novel oxazolidinone derivatives, processes for making compounds as well as antimicrobial pharmaceutical compositions containing said derivatives as active ingredients and methods of treating microbial infections with the said derivatives. Formula (I): wherein Q is formula (II): or formula (III).
--------------------------------------------------------------------------------

METHOD FOR PRODUCTION OF SINGLE- AND MULTI-LAYER MICROCAPSULES

(WO2007023495) 01.03.2007 B01J 13/12 TAGRA BIOTECHNOLOGIES LTD.
The present invention provides methods for microencapsulation of active ingredients for topical application, whereby single-layer and multi-layer, preferably double-layer, microcapsules, are obtained. The microcapsules protect the active ingredients, maintain their original activity throught processing, formulation and storage, and enable controlled release of the active ingredient only upon application onto the skin. The microcapsules consist of a cone made of an encapsulated active ingredient and one or more shells of the same of different wall-forming polymer. The microencapsulation methods of the present invention are based on the solvent removal method.
--------------------------------------------------------------------------------

VASOACTIVE KIT AND COMPOSITION AND USES THEREOF

(WO2007023396) 01.03.2007 None FOAMIX LTD.
The present invention relates to a therapeutic kit to provide a safe and effective dosage of a vasoactive agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition including: a vasoactive agent; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight, a surface- active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a ge...
--------------------------------------------------------------------------------

THERAPEUTICALLY ACTIVE a-MSH ANALOGUES

(WO2007022774) 01.03.2007 C07K 14/685 ACTION PHARMA A/S
The invention describes peptide analogues of a-melanocyte-stimulating hormone (a-MSH), which posses an increased efficay compared to the native a-MSH peptide. The a-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to a-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.
--------------------------------------------------------------------------------

METHOD FOR TREATING COFFEE FRUITS

(WO2007022610) 01.03.2007 A23F 5/02 ARCH QUMICA BRASIL LTDA.
A method for treating coffee fruits with or without the pulp, comprising the step of contacting the coffee fruits with a solution of a composition selected from the group consisting of active chorine-releasing inorganic and organic compositions, such as calcium oxychloride, dichloroisocyanuric acid and sodium and potassium salts thereof and trichloroisocyanuric acid diluted in a liquid vehicle, for a period of time sufficient to disinfect the coffee skin, pulp and beans, avoid fermentation thereof and neutralize metabolic chemical compositions that are detrimental to flavor, aroma and acidity degree of the coffee and to its quality.
--------------------------------------------------------------------------------

REDUCING MYOCARDIAL DAMAGE AND THE INCIDENCE OF ARRHYTHMIA ARISING FROM LOSS, REDUCTION OR INTERRUPTION IN CORONARY BLOOD FLOW

(WO2007022568) 01.03.2007 A61P 9/06 WEISS, Steven, Michael
A method and composition is disclosed for reducing the extent of cardiac arrhythmias, both resulting from loss, decrease or interruption to the blood supply such as may happen during a heart attack or during cardiac surgery, in mammals. In particular, the present invention relates to a method of limiting or preventing cardiac cell damage and/or death, and limiting or preventing lethal or non-lethal cardiac arrhythmias, in a human, by administering to the cardiac cells a compound which selectively blocks or partially blocks persistent sodium currents and/or persistent sodium channels of cardiac cells. The composition involves any physiologically acceptable chemical or pharmaceutical composition comprising as its active ingredient a cardiac p...
--------------------------------------------------------------------------------

ANTI-INFLAMMATORY ACTIVITY OF PHENETHYLISOTHIOCYANATE (PEITC) AND THE BARBAREA VERNA SEED PREPARATION CONTAINING THIS COMPOUND

(WO2007022434) 22.02.2007 A61K 36/31 RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
The subject of this invention is the anti-inflammatory activity of a formulation of Barbarea verna (upland cress, early winter cress, or winter cress) seed preparation (BSP) containing phenethylisothiocyanate as its main active ingredient. BSP is a promising anti-inflammatory agent, which can be used for treatment of many inflammation-related conditions, including but not limited to rheumatoid and osteoarthritis, acute and chronic pains, lupus, irritable bowl disease, cancer and metabolic syndrome.
--------------------------------------------------------------------------------

PHARMACEUTICAL FORMULATIONS FOR SUSTAINED DRUG DELIVERY

(WO2007022254) 22.02.2007 A61K 47/48 PRAECIS PHARMACEUTICALS, INC.
Sustained delivery formulations comprising a water-insoluble complex of a peptidic compound (e.g., a peptide, polypeptide, protein, peptidomimetic or the like) and a carrier macromolecule are disclosed. The formulations of the invention allow for loading of high concentrations of peptidic compound in a small volume and for delivery of a pharmaceutically active peptidic compound for prolonged periods, e.g. , one month, after administration of the complex. The complexes of the invention can be milled or crushed to a fine powder. In powdered form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. In a preferred embodiment, the peptidic compound of the complex is an LHRH analogue, preferably an LHRH antagoni...
--------------------------------------------------------------------------------

CLEANSING COMPOSITIONS CONTAINING FILM

(WO2007022229) 22.02.2007 C11D 9/22 COLGATE-PALMOLIVE COMPANY
A composition comprising a cleanser base and a plurality of film pieces, wherein the composition has a moisture content of about 22% or less. Also, a method of making a composition, comprising the steps of combining pieces of film with a cleansing material to make a cleansing mixture, and forming the mixture into a product of desired shape and size. Also, A method of delivering an active material during cleansing, comprising cleansing with water and a composition, wherein the composition comprises a plurality of film pieces, said film pieces comprising an active material and a polymer selected from water-soluble polymers, water- dispersible polymers, and combinations thereof.
--------------------------------------------------------------------------------

TOPICAL DELIVERY WITH A CARRIER FLUID

(WO2007022090) 22.02.2007 A61K 9/12 COLLEGIUM PHARMACEUTICAL, INC.
Aerosol spray formulations capable of delivering high concentratio of active agent-containing materials and/or excipient are described herein. The formulation contains a carrier fluid, a propellant, and a therapeutic, prophylactic, cosmeticeutical and/or inert solid suspended, dissolved, or dispersed in the formulation. The active ingredient may be any pharmaceutically active agent, but is preferably an antibiotic, an antihistamine, an anesthetic, an anti-inflammatory, and/or an astringent. In one embodiment, the active agent is an antifungal agent. In another embodiment, the active agent is a cosmeticeutical. The active agent can optionally be dispersed on, or associated with, a carrier powder. The carrie fluid is a highly volatile silicon...
--------------------------------------------------------------------------------

NEW SKIN IMPROVING COMPOSITION

(WO2007021240) 22.02.2007 A61K 8/97 TRICUTAN AB
The present invention relates to a composition for increasing the firmness and elasticity of the skin, in particular photo-damaged skin. The composition comprises a unique combination of active substances, i.e. asiatic acid, tetrahydrodiferuloylmethane and ursolic acid that together make the facial muscles contract, thus acting as an anti-ageing composition.
--------------------------------------------------------------------------------

HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME

(WO2007021067) 22.02.2007 C07C 233/75 AMOREPACIFIC CORPORATION
Disclosed is a hydroxybenzamide derivative represented by the following Formula (1). A method for preparing the same and a cosmetic composition comprising the same are also disclosed. More particularly, the hydroxybenzamide derivative is obtained by reacting a hydroxybenzoic acid having a protecting group introduced thereto with a hydroxyphenyl amine to form a benzamide derivative and by hydrolyzing the benzamide derivative in an aqueous base solution to form a hydroxybenzamide derivative. The cosmetic composition comprising the hydroxybenzamide derivative as an active ingredient has excellent anti-oxidative, anti-aging and skin wrinkle- alleviating effects. wherein R1 represents a C1 ~ C10 alkyl group, and n is an integer ranging fro...
--------------------------------------------------------------------------------

COSMETIC METHOD FOR THE TARGETING OF WRINKLES

(WO2007020536) 22.02.2007 A61K 8/25 L'ORAL
A subject-matter of the invention is a cosmetic method for caring for wrinkled skin, for the purpose of softening the wrinkles, comprising the successive stages: (a) of topical application to the wrinkled areas of a first composition including a pulverulent phase comprising porous particles which comprise at least one antiwrinkle active principle at least partially absorbed in the said particles, the said composition being substantially devoid of solvent for the said active principle, and (b) of topical application to the skin of the face comprising at least the said areas of a second composition including a fatty and/or aqueous phase comprising a solvent for the said active principle.
--------------------------------------------------------------------------------

N-(PYRIDIN-4-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS

(WO2007016358) 08.02.2007 C07D 211/72 MERCK &CO., INC.
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hype...
--------------------------------------------------------------------------------

TOPICAL SKIN PROTECTANT AND ANTI-PRURITIC COMPOSITIONS

(WO2007016147) 08.02.2007 A61K 31/5375 STIEFEL LABORATORIES, INC.
Topical skin protectant compositions, and more particularly anti-pruritic skin protectant compositions, comprising a skin protective ingredient, a therapeutically effective amount of a pharmaceutically active agent comprising an anesthetic agent or derivative thereof, an oleaginous solvent comprising a substance other than the skin protective ingredient, and an aqueous solvent. These skin protectant compositions are capable of temporarily or permanently reducing, inhibiting, treating, ameliorating, or preventing pruritic skin conditions, as well as other related skin conditions. These compositions are further capable of restoring or repairing a skin lipid barrier of a mammal.
--------------------------------------------------------------------------------

METHOD FOR RETARDING SYSTEMIC DELIVERY RATE FOR EASILY ABSORBABLE ACTIVE AGENTS

(WO2007016146) 08.02.2007 A61F 13/00 MACROCHEM CORPORATION
Drugs such as hormones, which are easily absorbable through the stratum corneum into the vascular network, are administered to the skin of a patient in an absorption retarding matrix material, thereby retarding the rate at which the drug penetrates into and through the skin.
--------------------------------------------------------------------------------

METAL OXIDE COATING OF WATER INSOLUBLE INGREDIENTS

(WO2007015243) 08.02.2007 B01J 13/02 SOL-GEL TECHNOLOGIES LTD.
The invention relates to process for coating a solid, water-insoluble particulate matter, with a metal oxide comprising: (a) contacting the solid water-insoluble particulate matter with a cationic additive in an aqueous medium to obtain a dispersion of said particulate matter having a positive zeta potential; (b) coating the solid water-insoluble particulate matter by precipitation of a metal oxide salt onto the surface of the particulate matter, forming a metal oxide layer thereon; and (c) aging said coating layer. The invention further relates to coated particulate matter obtained by the process and to compositions comprising solid, water-insoluble particulate matter, coated by a metal oxide layer, the particulate matter being a dermatolo...
--------------------------------------------------------------------------------

STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF

(WO2007012977) 01.02.2007 A61K 31/573 FOAMIX LTD
A composition and therapeutic kit including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam; wherein the pressurized product comprises a foamable composition including: i. a steroid; ii. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight; iii. a surface-active agent; iv. about 0.01 % to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; v. water; and vi. liq...
--------------------------------------------------------------------------------

TOPICAL FORMULATIONS CONTAINING SPOROPOLLENIN

(WO2007012857) 01.02.2007 A61K 8/97 UNIVERSITY OF HULL
Topical formulation containing an active substance which is chemically or physically bound to, or encapsulated within, an exine shell of a naturally occurring spore. The active substance can be released from the exine shell on application to a living or non- living surface. The invention may be used to provide gradual release of the active substance over a period of time subsequent to application of the formulation to the surface.
--------------------------------------------------------------------------------

USES OF SPOROPOLLENIN

(WO2007012856) 01.02.2007 A61K 8/97 UNIVERSITY OF HULL
The invention provides the use of an exine shell of a naturally occurring spore, or a fragment thereof, as an antioxidant, for instance in a formulation containing an active substance. Also provided is a method for reducing rancidity, or other oxidative degradation, of a substance or composition, by encapsulating the substance or composition in, or chemically or physically binding it to, or mixing it with, an exine shell of a naturally occurring spore or a fragment thereof.
--------------------------------------------------------------------------------

NOVEL USE OF ORGANIC COMPOUNDS

(WO2007009657) 25.01.2007 A23L 1/30 DSM IP ASSETS B.V.
The present invention is directed to the use of a compound selected from the group consisting of -carotene, lutein, lycopene and -cryptoxanthin, and mixtures thereof and combinations thereof with CoQ-I O for maintaining the energy metabolism, the energy flow and/or the energy production in skin or of skin of animals including humans, for maintaining the respiratory function of the skin of animals including humans, for energizing the skin, maintaining and supporting the radiance and natural glow of the skin of animals including humans and for promoting a healthy appearance of the skin of animals including humans for preventing UV-A radiation-induced mtDNA mutagenesis in skin of animals including humans, as well as for the manufactu...
--------------------------------------------------------------------------------

PROTEIN COMPOSITIONS FOR PROMOTING WOUND HEALING AND SKIN REGENERATION

(WO2007009019) 18.01.2007 A61K 38/46 ESSENTIAL SKINCARE, LLC
Methods for stimulating proliferation and inhibiting death of cells in the epidermis and dermis of wounded and non-wounded as well as transplanted mammalian skin and transplanted skin cell suspensions are described. The methods include the steps of administering to an area of wounded or non-wounded skin therapeutically effective amounts of 1-antitrypsin, alkaline phosphatase (such as placental alkaline phosphatase), transferrin, and 1-acid glycoprotein in compositions that contain at least two of these proteins, or their active derivatives, as the major active components. The compositions can be administered topically and/or by injection, or both. The invention also provides regimens for restoring or maintaining the strength and thickness o...
--------------------------------------------------------------------------------

NONSTEROIDAL IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF

(WO2007007208) 18.01.2007 A61K 9/12 FOAMIX LTD.
A composition and therapeutic kit including an aerosol packaging assembly including a container accommodating a pressurized product and an outlet capable of releasing a foamable composition, including a nonsteroidal immunomodulating agent as a foam. The foamable composition includes: i. a nonsteroidal immunomodulating agent; ii. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight; iii. a surface-active agent; iv. about 0.1 % to about 5% by weight of a therapeutically active foam adjuvant, selected from the group consisting of a fatty alcohol, a fatty acid, a hydroxyl fatty acid; and mixtures...
--------------------------------------------------------------------------------

RETINOID IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF

(WO2007007198) 18.01.2007 A61K 9/12 FOAMIX LTD.
A composition and therapeutic kit including an aerosol packaging assembly including a container accommodating a pressurized product and an outlet capable of releasing a foamable composition, including a retinoid as a foam. The foamable composition includes: i. a retinoid; ii. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight; iii. a surface-active agent; iv. about 0.01 % to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; v. water; and vi. liquefied or compressed ...
--------------------------------------------------------------------------------

COMPOSITION COMPRISING AN EXTRACT OF CRINUM ASIATICUM LINNE HAVING ANTI-ALLERGIC AND ANTI-INFLAMMATORY ACTIVITY

(WO2007004832) 11.01.2007 A61K 8/97 BIOLAND LTD.
The present invention is related to a topical composition and cosmetic composition comprising an extract of Crinum asiaticum Linne as an active ingredient in an amount effective to treat and alleviate allergy and inflammatory diseases. The extract of Crinum asiaticum Linne is very useful in the alleviation or treatment of allergy and inflammatory disease as a form of topical medicament or cosmetic composition.
--------------------------------------------------------------------------------

COSMETIC COMPOSITION CONTAINING AS AVAILABLE INGREDIENT THE EXTRACTS OF EQUISETUM ARVENSE L.

(WO2007004771) 11.01.2007 A61K 8/00 AMOREPACIFIC CORPORATION
The present invention relates to a composition containing, as active ingredients, an Equisetum arvense extract and at least one selected from the group consisting of a Lonicera japonica extract, a Primus armeniaca extract, a Plantago asiatica extract and a Coix lacryma-jobi extract, and more particularly to a composition having the effects of stimulating the growth of keratinocytes, scavenging active oxygen, reducing the biosynthesis of MMP-I and thus stimulating type 1 procollagen, and preventing skin aging.
--------------------------------------------------------------------------------

COMPOSITION FOR DERMATOLOGICAL TREATMENT

(WO2007003915) 11.01.2007 A61Q 19/00 MOTSI, Tulani
The present invention relates to the treatment of dermatological conditions. Particularly, although not exclusively, the present invention relates to a composition containing a number of active agents and a method of using Said combination to reduce the appearance of spots and skin roughness. Compositions, methods and medicaments are described for treating ageing, eczema, dermatitis, rosacea, acne, psoriasis, light damage, sunburn, photoageing, sub-optimal wound healing, scarring, alopecia, tendon injury, thermal injury.
--------------------------------------------------------------------------------

METHOD OF ENHANCED DRUG APPLICATION

(WO2007002880) 04.01.2007 A61K 9/18 JR CHEM, LLC
Methods of treating skin in need thereof are disclosed including applying a drug or active agent or formulation thereof to the skin of a user and applying a sealer thereto. The methods are useful in actively enhancing penetration of the actives immediately upon application to skin, sealing the skin surface to prevent removal of the drug or active agent, holding the drug or active agent in a reservoir film, and/or enhancing long term penetration of the drug or active agent.
--------------------------------------------------------------------------------

PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

(WO2007002433) 04.01.2007 C07D 471/04 PLEXXIKON, INC.
Compounds of formula III which are active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. (Formula III).
--------------------------------------------------------------------------------

PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

(WO2007002325) 04.01.2007 C07D 471/04 PLEXXIKON, INC.
Compounds of formula III which are active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
--------------------------------------------------------------------------------

PERSONAL CARE COMPOSITIONS COMPRISING ALPHA-GLUCANS AND/OR BETA-GLUCANS

(WO2007001904) 04.01.2007 A61Q 5/00 THE PROCTER &GAMBLE COMPANY
Personal care compositions containing at an alpha-glucan and/or beta-glucan; at least one additional skin and/or hair care active selected from the group consisting of sugar amine, vitamin B3, retinoids, peptides, phytosterol, dialkanoyl hydroxyproline, hexamidine, salicylic acid, n-acyl amino acid compounds, sunscreen actives, water soluble vitamins, oil soluble vitamins, hesperedin, mustard seed extract, glycyrrhizic acid, glycyrrhetinic acid, carnosine, Butylated Hydroxytoluene (BHT) and Butylated Hydroxyanisole (BHA), menthyl anthranilate, cetyl pyridinium chloride, ergothioneine, vanillin or its derivatives, diethylhexyl syrinylidene malonate, melanostatine, sterol esters, tetrahydrocurcumin, their derivatives, their precursors, and co...
--------------------------------------------------------------------------------

A PRODUCT RELEASE SYSTEM TO ATOMIZE COSMETIC HAIR AND SKIN CLEANING COMPOSITIONS

(WO2007001844) 04.01.2007 A61Q 5/02 THE PROCTER &GAMBLE COMPANY
A product release system for atomizing cosmetic hair or skin cleaning compositions is described, which has (a) pressure-resistant packaging, (b) a capillary-containing spray head, and (c) a propellant-containing cosmetic composition, which contains at least one wash-active surfactant. The atomization is done using the capillary. The capillary preferably has a diameter of 0.1 to 1 mm and a length of 5 to 100 mm. The spray rate is preferably 0.01 to 5 g/s. The composition can particularly be gel-like.
--------------------------------------------------------------------------------

COMPOSITION AND METHOD OF PROTECTION AGAINST UV IRRADIATION

(WO2007001506) 04.01.2007 A61K 8/00 PURE LABORATORIES, LLC
The present invention relates to a composition for use in a nutritional product, dietary supplement, or pharmaceutical compound wherein such composition is used to protect the skin against the effects of ultraviolet (UV) irradiation from the sun or other sources, including but not limited to sunburn, skin redness, swelling, immune suppression, photo-aging, photodamage, and skin cancer. The invention relates to a composition containing a variety of antioxidants, vitamins, and herbal ingredients. The present invention further relates to a method of administering a therapeutically effective amount of the composition ingredients to protect the skin against the effects of UV irradiation.
--------------------------------------------------------------------------------

NON-IRRITATING COMPOSITIONS

(WO2007001484) 04.01.2007 A61K 8/00 PLAYTEX PRODUCTS, INC.
The present invention provides a base composition that allows for the formulation of non-irritating cosmetic and/or dermatological compositions. The base composition includes one or more of electrolyte, buffer, mild preservative, lubricant, or any combinations thereof. It is preferred that one or more of the above components are eye-safe and/or eye-compatible. The present invention also provides photoprotective cosmetic and/or dermatological compositions that include the base composition and one or more sunscreen active components and are non- irritating to mammalian eyes.
World  Patents Published  in 2008
 
World Patents Published in 1990-2006
...or use our Search Engine
to search for patent
documents by number.
Search for anything.
Simply type the words in
the box..
Clck to enlarge and view details
WORLD PATENTS IN ACTIVES FOR SKIN CARE GRANTED IN  2007
This list includes patent documents published by the World Intellectual Property Organization (WIPO). The list was retrieved by searching the claims section of all patent applications
published. Salient search terms include skin care active ingredients having properties such as anti-ageing, anti-wrinkle, antioxidant, acne control benefits, skin whitening or lightening,
blemish removal, etc. This category includes technology related to the synthesis and delivery of actives such as peptides, exfoliants, α-hydroxy acids, herbals, free radical scavenger, "green"
derived molecules, etc.